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Phosphoinositide 3-kinases (PI3Ks) are considered promising drug targets in oncology. In this issue of
Cancer Cell, Schmid et al. demonstrate that the PI3Kg isoform is required for inflammatory myeloid cells
to traffic to tumors. Though tumor cells do not express PI3Kg, selective inhibition of this isoform suppresses
tumor growth and angiogenesis.Entry of inflammatory cells into the tumor
microenvironment is now considered
a key feature of tumorigenesis, promoting
hallmarks of cancer including angiogen-
esis and invasion (Hanahan and Wein-
berg, 2011; Mantovani and Sica, 2010).
Consequently, agents that target inflam-
matory cell recruitment might have thera-
peutic benefit in cancer while avoiding the
intrinsic propensity of cancer cells to
become drug-resistant. The signals that
attract myeloid cells from the blood to
enter tumor tissue are complex and act
through multiple distinct receptor sub-
types (Figure 1). This presents a challenge
for identifying a suitable target for drug
development. A paper in the current issue
(Schmid et al., 2011) demonstrates that
diverse extracellular factors converge
upon a single signaling enzyme (PI3Kg)
to trigger myeloid cell adhesion to endo-
thelial cells (ECs). Specific blockade of
PI3Kg is sufficient to reduce tumor inflam-
mation and angiogenesis, indirectly sup-
pressing the growth of tumors in vivo.
The study starts by addressing the
question of which integrins mediate the
attachment of myeloid cells to ECs and
invasion into tumors. In the experimental
models used, monocyte-derived cells,
rather than neutrophils, are the major
subset of myeloid cells that populate
and persist in tumor tissue (Figure 1).
The tumor cells as well as resident
myeloid cells secrete soluble factors that
recruit additional myeloid cells, amplifying
inflammation. These factors include che-
mokines that signal through G protein-
coupled receptors (GPCRs), VEGF that
activates receptor tyrosine kinases
(RTKs), and cytokines such as IL-1b that
signal via the TLR/IL-1R family of recep-
tors that are coupled to intracellular tyro-sine kinases (TKs). Surprisingly, each of
these diverse stimuli promoted adhesion
to EC through activation of the same in-
tegrin molecule, a4b1. This led the inves-
tigators to hypothesize that a common
signaling pathway is triggered by diverse
receptors on myeloid cells to increase
the avidity of a4b1, a process called
‘‘inside-out’’ signaling. Testing of a large
panel of chemical inhibitors indicated
that PI3Ks might be key intermediates in
the inside-out signaling pathway.
PI3Ks are a family of lipid kinases that
phosphorylate phosphatidylinositol (PI)
and its derivatives to generate 3-phos-
phorylated phosphoinositides (Vanhaese-
broeck et al., 2010). The main product of
class I PI3Ks, phosphatidylinositol-3,4,5-
trisphosphate (PIP3), initiates signaling
pathways essential for cell growth, prolif-
eration, survival, and migration down-
stream of growth factors and oncopro-
teins. Two PI3K enzymes (PI3Ka and
PI3Kd) are primarily activated by
TK-based signals. A third isoform,
PI3Kb, can be activated either by TKs or
by GPCRs. Genetic analysis of human
cancer has shown that the PI3Ka isoform
plays a dominant role (Figure 1). Gain-of-
function mutations in the PIK3CA gene,
which encodes the catalytic subunit
PI3Ka, are found in a broad spectrum of
tumors, with incidence of 30%–40% in
some cancer subtypes (Samuels and
Ericson, 2006). PI3Kb and PI3Kd activity
might also be important in some tumors
(Ciraolo et al., 2008; Jia et al., 2008;
Lannutti et al., 2011). The fourth member
of the class I PI3K subgroup, PI3Kg, has
received less attention as a drug target
in oncology for two main reasons. First,
PI3Kg is activated by GPCRs but has
not been demonstrated to function inCancer Cellsignals emanating from TKs, which are
the dominant drivers of the cancer pheno-
type. Second, PI3Kg is mainly found in
leukocytes, with few tumors showing
prominent expression or function of this
isoform. Hence, one would not expect
selective inhibitors of PI3Kg to suppress
directly the proliferation or survival of
most cancer cells. Yet what if PI3Kg is
integral for the function of other cells in
the tumor microenvironment?
Schmid et al. (2011) provide abundant
evidence to support this idea. The team
used a variety of experimental ap-
proaches to assess the role of PI3Kg:
knockout mice; knockin mice with
a kinase-dead mutation in PI3Kg; selec-
tive inhibitors of PI3Kg and other iso-
forms; and RNAi-mediated knockdown.
In each case, interfering with PI3Kg
function strongly blocked the activation
of integrin a4b1. In addition, receptor-
mediated increases in PIP3 and phos-
phorylation of the PI3K effector AKT
were absolutely dependent on PI3Kg
and not other isoforms. The results were
comparable whether the cells were stimu-
lated through GPCRs (with the chemo-
kines SDF-1a or C5a), through RTKs
(with growth factors VEGF or CSF-1), or
via receptors linked to cytoplasmic TKs
(with cytokines IL-1, IL-6, or TNFa).
Furthermore, only PI3Kg knockdown pre-
vented myeloid cells from trafficking to
tumors in mice. This indicates that what-
ever mix of chemotactic factors is present
in vivo, the signal to invade the tumor
requires only the PI3Kg isoform.
These results challenge the paradigm
that PI3Kg functions exclusively in
GPCR signaling. To lend weight to this
observation, the investigators undertook
a major effort to understand the19, June 14, 2011 ª2011 Elsevier Inc. 693
Figure 1. p110g in Myeloid Cells Mediates Adhesion to Endothelial Cells, Driving Tumor Inflammation and Progression
Bone marrow-derived myeloid cells enter tumor sites by first adhering to endothelial cells in the local vasculature. Adhesion is driven by extracellular signals that
increase avidity of the integrin a4b1. The extracellular signaling molecules are produced by both the tumor cells and local macrophages, and include chemokines,
growth factors, and cytokines. Receptors for these diverse ligands each stimulate PI3Kg, linking to the catalytic subunit p110g through either the p87 or p101
regulatory subunits and through the Ras GTPase. Myeloid cells entering the tumor microenvironment mature into macrophages (CD11b+Gr-1loF4/80+) that
secrete a partially overlapping set of chemotactic and angiogenic factors. The inflammation associated with progressive recruitment of myeloid cells enhances
tumor growth and angiogenesis.
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PI3Kg isoform to couple to TK-based
signals. They show that treatment of
myeloid cells with VEGF-A causes the
cognate RTK (VEGFR1) to physically
associate with PI3Kg but not other class
I isoforms. They define a pathway in which
RTK engagement promotes activation of
the Ras GTPase, which recruits and acti-
vates PI3Kg via its regulatory subunit
p87 (Figure 1). A distinct regulatory
subunit, p101, plays a complementary
role in activating PI3Kg downstream of
GPCRs and Ras in this system. It will be
interesting to see whether this division of
labor is common to other leukocyte
subsets. A key experiment showed that
knockdown of p87 and p101 had additive
effects on suppressing myeloid cell traf-694 Cancer Cell 19, June 14, 2011 ª2011 Elsficking to tumors in mice. This indicates
that chemotactic factors in vivo likely
include distinct stimuli acting through
TKs and GPCRs.
Suppressing PI3Kg clearly prevents
accumulation of certain myeloid popula-
tions in tumors; does this have any impact
on tumor growth? Schmid et al. (2011)
demonstrate that transplanted and spon-
taneous tumors develop more slowly in
PI3Kg-deficient mice. In each model,
suppression of PI3Kg resulted in impaired
angiogenesis. This probably results from
the absence of myeloid cells that secrete
angiogenic factors such as VEGF
(Figure 1), rather than a defect in ECs.
Indeed, bone marrow chimera experi-
ments showed that the defective cell
type in the tumor microenvironment is ofevier Inc.hematopoietic origin. Treating mice with
selective PI3Kg inhibitors also reduced
tumor growth, even though the com-
pounds had no direct impact on cancer
cell proliferation in vitro. A key experiment
showed that PI3Kg inhibitors do not
further reduce tumor growth in wild-type
mice bearing PI3Kg-deficient blood cells.
These results demonstrate that PI3Kg
inhibitors act via a cancer cell-extrinsic
manner to suppress tumor-associated
inflammation and angiogenesis.
Drug discovery pipelines include
a growing number of PI3K inhibitors in
clinical trials for oncology, autoimmunity,
allergy, and other disease states
(Workman et al., 2010). Until now, PI3Kg
has been considered mainly as a target
for inflammatory diseases such as arthritis
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of PI3Kg-selective compounds has been
slower than other target profiles. Although
the conclusions of Schmid et al. (2011)
need to be validated in other models,
the current data support the novel con-
clusion that the antiinflammatory potential
of PI3Kg inhibitors might be harnessed
to disrupt the tumor microenvironment
and slow the progression of cancer. The
fact that most solid tumor cells do not
express PI3Kg should limit the de-
velopment of resistance to PI3Kg inhibi-
tors. These considerations should
increase momentum for PI3Kg inhibitor
programs. To be sure, there remain
challenges to developing treatments tar-
geting cancer inflammation. Should such
agents be given as preventive therapy,
or will they be effective in treating estab-
lished malignancies? These questions
can be addressed initially through addi-tional preclinical studies. If PI3Kg-
targeted agents can limit the growth of
established tumors, an important im-
plication is that drugs targeting all class I
PI3Ks (or just PI3Ka and PI3Kg) should
be more effective than selective PI3Ka
inhibitors, even in patients whose tumors
are driven by PI3KCA mutations.
ACKNOWLEDGMENTS
The authors thank Christian Rommel for helpful
suggestions.
REFERENCES
Ciraolo, E., Iezzi, M., Marone, R., Marengo, S., Cur-
cio, C., Costa, C., Azzolino, O., Gonella, C., Rubi-
netto, C., Wu, H., et al. (2008). Sci. Signal. 1, ra3.
Hanahan, D., and Weinberg, R.A. (2011). Cell 144,
646–674.
Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L.,
Lee, S.H., Zhang, J., Signoretti, S., Loda, M.,Cancer CellRoberts, T.M., and Zhao, J.J. (2008). Nature
454, 776–779.
Lannutti, B.J., Meadows, S.A., Herman, S.E.,
Kashishian, A., Steiner, B., Johnson, A.J., Byrd,
J.C., Tyner, J.W., Loriaux, M.M., Deininger, M.,
et al. (2011). Blood 117, 591–594.
Mantovani, A., and Sica, A. (2010). Curr. Opin. Im-
munol. 22, 231–237.
Ru¨ckle, T., Schwarz, M.K., and Rommel, C. (2006).
Nat. Rev. Drug Discov. 5, 903–918.
Samuels, Y., and Ericson, K. (2006). Curr. Opin.
Oncol. 18, 77–82.
Schmid, M.C., Avraamides, C.J., Dippold, H.C.,
Franco, I., Foubert, P., Ellies, L.G., Acevedo,
L.M., Manglicmot, J.R., Song, X., Wrasidlo, W.,
et al. (2011). Cancer Cell 19, this issue, 715–727.
Vanhaesebroeck, B., Guillermet-Guibert, J., Grau-
pera, M., and Bilanges, B. (2010). Nat. Rev. Mol.
Cell Biol. 11, 329–341.
Workman, P., Clarke, P.A., Raynaud, F.I., and van
Montfort, R.L. (2010). Cancer Res. 70, 2146–2157.ROCK-Driven Actomyosin Contractility
Induces Tissue Stiffness and Tumor GrowthSandra Ku¨mper1 and Christopher J. Marshall1,*
1Cancer Research UK, Tumour Cell Signalling Unit, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK
*Correspondence: Chris.Marshall@icr.ac.uk
DOI 10.1016/j.ccr.2011.05.021
The tumor environment consists of tumor-associated cells, such as macrophages, fibroblasts, and extra-
cellular matrix, and has an important impact on tumor progression. In this issue of Cancer Cell, Samuel
et al. show that ROCK-driven actomyosin contractility increases tissue stiffness affecting epidermal homeo-
stasis, as well as tumor growth and progression.Tissues consist of cells and extracellular
matrix (ECM), and cells are tightly linked to
their extracellular environment through
adhesion receptorssuchas integrins.Within
a tissue, remodeling of the ECM can occur
as part of normal physiological processes
or in disease. ECM remodeling involves
both the physical force of tension acting
on the ECM and enzymatic action; for
example, by extracellular proteases or
enzymes that crosslink ECM components
such as collagen. An imbalance in the
relationship between cells and the extracel-
lular environment is found in diseases such
as cancer, and there is strong evidencethat increased tissue stiffness contributes
to tumor progression (Levental et al., 2009;
Paszek et al., 2005). Indeed, increased
tissue stiffness is the basis of physical
examination by palpation for cancer. Tissue
stiffening may result from ECM remodeling
that drives integrin clustering at the cell
surface and subsequent cytoskeletal
changes, resulting inchangesof intracellular
tension. Intracellular tension arises through
theactionofmyosin II in generatingactomy-
osin contractility. Actomyosin contractility
hasmultipleother roles inaddition tomuscle
contraction. It is essential for cyokinesis in
mitosis, cell adhesion, cell shape, and cellmovement (Vicente-Manzanares et al.,
2011). The level of actomyosin contractility
in tumor cells is a key determinant of
different modes of cell movement (Sanz-
Moreno and Marshall, 2010). An important
regulator of actomyosin contractility is the
familyofRho-associatedcoiled-coil forming
protein serine/threonine kinases (ROCKI
and ROCKII) that are activated by Rho
GTPases RhoA and RhoC. ROCKI and II
generate contractile force through phos-
phorylation of the myosin-binding subunit
of myosin phosphatase (MYPT1), LIM
kinase 2 (LIMK2), and possibly myosin
regulatory light chain (MLC2) (Figure 1A).19, June 14, 2011 ª2011 Elsevier Inc. 695
